The largest database of trusted experimental protocols

Visipaque 320 mg ml

Manufactured by GE Healthcare
Sourced in Norway, United States

Visipaque 320 mg/mL is a non-ionic, iso-osmolar contrast medium used for radiographic imaging procedures. It contains the active ingredient iodixanol, which enhances the visibility of internal structures during diagnostic imaging.

Automatically generated - may contain errors

2 protocols using visipaque 320 mg ml

1

Quantitative Angiographic Evaluation of Coronary Artery Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols
Coronary angiography was performed with the percutaneous radial or femoral approach using 6F diagnostic catheters (Cordis Corporation, Miami, Fla., USA) and the water-soluble, non-ionic, dimeric contrast medium iodixanol (Visipaque 320 mg/mL; G.E.Healthcare, Oslo, Norway). Coronary artery angiogram data was evaluated by experienced local staff blinded to treatment and was classified as 1-, 2- or 3-vessel disease according to the presence of a stenosis greater than 50% of lumen diameter. Stenosis of the left main coronary artery of > 50% of lumen diameter was considered to be 2-vessel disease. Inter-observer variability of angiographic classifications was 4.9%.
Further quantitative angiographic evaluation was performed using an established scoring system [16 (link)]. Coronary segments were graded as grade 0, 1, 2, 3, 4 or occlusion based on the presence of < 25%, < 50%, < 75%, ≥ 75% or occlusion defined as a > 95% diameter stenosis with a severely reduced or no antegrade flow, respectively. CAD severity score was calculated as the average grade of the diseased coronary segments (i.e. ≥ grade 1). CAD extent score was calculated for each patient based on the number of segments exhibiting lesions ≥ grade 1.
+ Open protocol
+ Expand
2

Coronary Vein Mapping Using 3rd Gen DSCT

Check if the same lab product or an alternative is used in the 5 most similar protocols
CTA images were acquired using 192-slice 3rd generation DSCT scanner (SOMATOM force, Siemens).12 (link) Prospective ECG-gated sequential acquisition was performed during end-systole (absolute delay x-458 ms delay) and mid-diastole (relative delay of 60–75%) or ECG-gated helical acquisition for patients with BMI ≥35 kg/m2 or with atrial fibrillation. Scans were performed using a single inspiratory breath hold. Iodixanol (Visipaque 320 mg/mL, GE Healthcare, Chicago, IL, USA) was administered into an antecubital vein. A volume of 80 to 100 mL at a flow rate of 4 mL/s was used for the image acquisition followed by 100 mL of normal saline. Acquisition was peformed during the (delayed) venous phase for optimization of vein opacification with contrast.
Volume-rendered images were created from CTA images of the coronary venous system and were analyzed. Visible LVS tributary branch veins were manually traced and counted by creating a new segmentation object for the venous system using the region growing function of Syngo.via® (Siemens). A septal LVS vein was defined as a GCV or AIV tributary branch that drains the LVS region medially (rightward) to the GCV/AIV and a diagonal LVS vein was a GCV or AIV tributary branch that drains the LVS region laterally (leftward) to the GCV/AIV. Vein angulations seen in the LVS region were also measured.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!